Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kukoamine B Mesilate in Sepsis
NCT04803955Phase 2Recruiting
- Sponsor
- Tianjin Chase Sun Pharmaceutical
- Start
- May 2021
- Primary completion
- May 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of kukoamine B in sepsis, sponsored by Tianjin Chase Sun Pharmaceutical. Started May 2021; status: recruiting.
02
Drugs
kukoamine B
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT04803955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04803955.